Go321
Phase 1
Go321 is one of 11 therapeutic programs targeting Solid Tumor Malignancies. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
17 competitors in Solid Tumor Malignancies
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Herceptin
RochePhase 2
Lumakras
AmgenPhase 2
Verzenio
Eli LillyPhase 2
Taxotere
AAvyxa
Phase 2
Faslodex
FFresenius Kabi USA, LLC
Phase 2
GV20-0251
GGV20 Therapeutics
Phase 2
KB707
KKrystal Biotech, Inc.
Phase 2
SC-Car.gpc3xil15.21 CAR T Cells
SSeattle Children's Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Solid Tumor Malignancies1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Go321. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]